Catalyst Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Catalyst Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-135	Closed	-$25K	–	428
2021 Q2	$25K	Buy	135 +5	+4%	+$858	﹤0.01%	351
2021 Q1	$20K	Sell	130 -24	-16%	-$3.71K	﹤0.01%	325
2020 Q4	$24K	Buy	+154	New	+$19.8K	﹤0.01%	308
2018 Q1	–	Sell	-13,000	Closed	-$1.55M	–	633
2017 Q4	$1.55M	Buy	13,000 +8,050	+163%	+$980K	0.06%	146
2017 Q3	$694K	Buy	+4,950	New	+$673K	0.03%	191
2016 Q2	–	Sell	-5,000	Closed	-$696K	–	631
2016 Q1	$696K	Sell	5,000 -5,175	-51%	-$760K	0.12%	137
2015 Q4	$1.94M	Hold	10,175	–	–	0.3%	91
2015 Q3	$1.59M	Sell	10,175 -20,000	-66%	-$3.65M	0.23%	109
2015 Q2	$5.46M	Buy	30,175 +30,000	+17,143%	+$5.18M	0.65%	66
2015 Q1	$30K	Hold	175	–	–	﹤0.01%	363
2014 Q4	$32K	Hold	175	–	–	﹤0.01%	363
2014 Q3	$29K	Buy	+175	New	+$28.7K	﹤0.01%	334

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return